Lexapro / Cipralex (Escitalopram) Tapering Guide

Escitalopram is an SSRI antidepressant. In the UK it is prescribed as generic escitalopram or Cipralex; in the US it is best known as Lexapro. It is licensed for depression, panic disorder, social anxiety, generalised anxiety, and OCD — and a large share of people taking it are treated for anxiety rather than depression. This guide and medication taper calculator are for planning how to get off antidepressants with your prescriber, not a dose instruction.

Dosage

Escitalopram is made as tablets and as a liquid. Tablets are commonly 5 mg, 10 mg, 15 mg and 20 mg, with orodispersible tablets in the same strengths. The UK liquid is oral drops at 20 mg/mL (1 mg per drop). In the US the equivalent is an oral solution at 1 mg/mL, given with an oral syringe.

Escitalopram is potent per milligram, so a dose that sounds small is still doing substantial work. If a plan you and your prescriber agree involves amounts below what a tablet allows, liquid is usually how that is done.

Escitalopram taper schedule

Choose a common starting dose to preview an example hyperbolic schedule you can take to your prescriber — free, no email required. This example has 22 steps and takes about 42 weeks in total. It is a planning tool, not a dose instruction.

Starting dose

Selected start: 10 mg/day · 1× daily
Taper speed: Moderate
Region (formulations): US
Modelled occupancy at start: ~78.3%

Tablet/liquid products used for dosing tips — not your location. Example uses US formulary; change region in the custom builder.

Swipe sideways to see every column.

Step	Daily (mg)	How to take it	Per dose × 1/day	Hold (weeks)
0	10	Your current dose — hold steady before step 1.	10 mg × 1	—
1	8	Measure 8 mL of 1 mg/mL oral solution (≈ 8 mg active ingredient). Use an oral syringe; confirm concentration on the bottle.	8 mg × 1	2
2	5	Take 1 × 5 mg Lexapro tablet (5 mg active ingredient total).	5 mg × 1	2
3	4.3	Measure 4.3 mL of 1 mg/mL oral solution (≈ 4.3 mg active ingredient). Use an oral syringe; confirm concentration on the bottle.	4.3 mg × 1	2
4	3.75	Measure 3.75 mL of 1 mg/mL oral solution (≈ 3.75 mg active ingredient). Use an oral syringe; confirm concentration on the bottle.	3.75 mg × 1	2
5	3.3	Measure 3.3 mL of 1 mg/mL oral solution (≈ 3.3 mg active ingredient). Use an oral syringe; confirm concentration on the bottle.	3.3 mg × 1	2
6	2.9	Measure 2.9 mL of 1 mg/mL oral solution (≈ 2.9 mg active ingredient). Use an oral syringe; confirm concentration on the bottle.	2.9 mg × 1	2
7	2.55	Measure 2.55 mL of 1 mg/mL oral solution (≈ 2.55 mg active ingredient). Use an oral syringe; confirm concentration on the bottle.	2.55 mg × 1	2
8	2.25	Measure 2.25 mL of 1 mg/mL oral solution (≈ 2.25 mg active ingredient). Use an oral syringe; confirm concentration on the bottle.	2.25 mg × 1	2
9	2	Measure 2 mL of 1 mg/mL oral solution (≈ 2 mg active ingredient). Use an oral syringe; confirm concentration on the bottle.	2 mg × 1	2
10	1.8	Measure 1.8 mL of 1 mg/mL oral solution (≈ 1.8 mg active ingredient). Use an oral syringe; confirm concentration on the bottle.	1.8 mg × 1	2
11	1.6	Measure 1.6 mL of 1 mg/mL oral solution (≈ 1.6 mg active ingredient). Use an oral syringe; confirm concentration on the bottle.	1.6 mg × 1	2
12	1.45	Measure 1.45 mL of 1 mg/mL oral solution (≈ 1.45 mg active ingredient). Use an oral syringe; confirm concentration on the bottle.	1.45 mg × 1	2
13	1.3	Measure 1.3 mL of 1 mg/mL oral solution (≈ 1.3 mg active ingredient). Use an oral syringe; confirm concentration on the bottle.	1.3 mg × 1	2
14	1.15	Measure 1.15 mL of 1 mg/mL oral solution (≈ 1.15 mg active ingredient). Use an oral syringe; confirm concentration on the bottle.	1.15 mg × 1	2
15	1.05	Measure 1.05 mL of 1 mg/mL oral solution (≈ 1.05 mg active ingredient). Use an oral syringe; confirm concentration on the bottle.	1.05 mg × 1	2
16	0.95	Measure 0.95 mL of 1 mg/mL oral solution (≈ 0.95 mg active ingredient). Use an oral syringe; confirm concentration on the bottle.	0.95 mg × 1	2
17	0.85	Measure 0.85 mL of 1 mg/mL oral solution (≈ 0.85 mg active ingredient). Use an oral syringe; confirm concentration on the bottle.	0.85 mg × 1	2
18	0.75	Measure 0.75 mL of 1 mg/mL oral solution (≈ 0.75 mg active ingredient). Use an oral syringe; confirm concentration on the bottle.	0.75 mg × 1	2
19	0.65	Measure 0.65 mL of 1 mg/mL oral solution (≈ 0.65 mg active ingredient). Use an oral syringe; confirm concentration on the bottle.	0.65 mg × 1	2
20	0.55	Measure 0.55 mL of 1 mg/mL oral solution (≈ 0.55 mg active ingredient). Use an oral syringe; confirm concentration on the bottle.	0.55 mg × 1	2
21	0.5	Measure 0.5 mL of 1 mg/mL oral solution (≈ 0.5 mg active ingredient). Use an oral syringe; confirm concentration on the bottle.	0.5 mg × 1	2

Rows highlighted: larger occupancy drop than target — consider smaller steps or longer holds. If symptoms are intolerable, return to the previous dose and talk to your prescriber.

Want a copy to keep?

The full escitalopram schedule is already shown below. Enter your email to also receive a PDF and HTML copy you can save or share with your prescriber — optional, and we never gate the schedule behind it.

It's not a substitute for medical advice. This calculator can help you visualise a tapering schedule but before making any changes to your medication plan it's necessary to consult a medical professional. Ask a psychiatrist — available after you request your protocol.

Dose vs occupancy

This example is spread across 22 gradual steps. The curve below shows why the last few milligrams matter most: at low doses, small dose changes produce large drops in serotonin-transporter occupancy.

What this shows: the non-linear relationship between dose and serotonin transporter (SERT) occupancy. The curve is flat at high doses — most transporters are already blocked, so a dose cut has little biological impact — and much steeper at low doses, where even a 1–2 mg reduction causes a disproportionately large drop in occupancy. Your taper steps are spaced along this curve so each step removes a similar amount of occupancy.

Modelled Hill-curve occupancy — illustrative only. PET-derived parameters vary by study; your prescriber may use different clinical targets. Small mg changes near zero can still produce large occupancy shifts.

Want a full taper protocol?

This page shows a quick schedule for this drug. For the guided path — pre-taper risk quiz, formulation-aware steps, and email delivery — continue in the builder.

Start taper protocol →

How to Taper Off Lexapro (Escitalopram) Safely

How to taper off Lexapro (escitalopram) safely starts with recognising its potency: small milligram changes can mean large shifts in serotonin-transporter occupancy. Coming off escitalopram is usually planned as a hyperbolic reduction with your prescriber — shrinking steps — rather than a linear “cut by 5 mg” idea. The calculator on this page drafts an example of that pattern; it does not tell you what to take.

Escitalopram is the S-enantiomer of citalopram: citalopram is a mixture of two mirror-image forms, and escitalopram is the one that does most of the work. That is why the usual doses are roughly half those of citalopram. The two are not interchangeable milligram for milligram. In the UK it is prescribed as generic escitalopram or Cipralex; in the US it is best known as Lexapro.

About this guide

This is general information about escitalopram for people taking it, thinking about starting or stopping. It is not personal medical advice, and it does not tell you what dose to take or how to change one. Those decisions belong with the prescriber who knows your history.

If anything here differs from what your own doctor or pharmacist has told you, go with them.

How long people usually take it

Escitalopram is not usually a short course. The product information states that treatment for depression should generally continue for at least six months after recovery, and NICE gives the same advice, with regular review. For social anxiety disorder the product information notes that a full twelve weeks may be needed simply to consolidate the initial response. For people who have had several episodes, or who are at higher risk of relapse, treatment is often considerably longer.

This matters if you are thinking about stopping, because stopping early carries a real risk. In a UK trial in general practice, among people who had been well enough that stopping seemed reasonable, 56% of those who stopped became unwell again within a year, compared with 39% of those who continued. That is not an argument for staying on antidepressants indefinitely, and many people come off them successfully and stay well. It is an argument for the timing being a decision you make deliberately with your prescriber, rather than one you make on the day you run out.

What people commonly notice while taking it

The effects listed as very common in the UK product information are headache and nausea. Common ones include difficulty sleeping, drowsiness, dizziness, tremor, diarrhoea, constipation, vomiting, dry mouth, increased sweating, tiredness, reduced sex drive and difficulty with orgasm or ejaculation.

Sexual side effects occur with all SSRIs and are among the more frequent reasons people ask about coming off. They are worth raising in an appointment rather than tolerating silently, because there are sometimes options.

Many early effects settle over the first two or three weeks. Feeling emotionally flat, or less able to feel things strongly, is not in the formal very common list but is described often enough by patients to be worth naming here.

Escitalopram can affect your ability to drive or operate machinery, particularly early on or after a change in dose. There is a small increase in bleeding risk, and a small risk of low sodium in the blood, which is more likely in older people and can cause confusion or unsteadiness.

Escitalopram can also affect the electrical rhythm of the heart at higher doses. This is why the maximum licensed dose for adults is 20 mg a day, and lower, usually up to 10 mg, for people over 65 or with liver problems. Tell your prescriber if you have a heart rhythm problem, a family history of sudden cardiac death, or are taking other medicines that affect heart rhythm. This is a reason the dose ceiling is where it is, not a reason to be alarmed at a normal dose.

Thinking about stopping

There are many different reasons for people to think about stopping. This can be that they have been well for a long time, the side effects have come to outweigh the benefit, they are planning a pregnancy, or circumstances have changed.

What helps is having the conversation before the plan rather than after it. Some questions that are worth taking to the appointment:

how long you have been taking it, and how long it has been since you last felt unwell
whether anything in the next few months makes this a difficult time to start
what happened if you have tried before, and what you would do differently
how the two of you will tell withdrawal symptoms from the original problem returning
who you contact, and how quickly, if it becomes difficult

One thing is worth being clear about: escitalopram should not be stopped abruptly. NICE advises against stopping antidepressants suddenly except in rare and serious circumstances, such as a severe reaction to the medicine.

What coming off Lexapro actually feels like, week by week

Escitalopram leaves the body over roughly a day and a bit. Its half-life, the time for the level in the blood to halve, is around 27 to 32 hours. That means when a reduction is larger than someone can comfortably absorb, the effects usually appear within a few days rather than within hours. Many people find the reduction from the top of the dose range straightforward and then find the lower end considerably harder.

What people may describe is dizziness or lightheadedness, brief electric-shock sensations often called brain zaps, nausea, difficulty sleeping, tearfulness, and a jittery, restless anxiety.

How common is this? The research does not give a clean answer, and it is worth being straight about that. A large review published in 2024 found that about a third of people had at least one symptom after stopping an antidepressant, but also that about one in six had symptoms after stopping a dummy tablet, leaving roughly one in six or seven that could be attributed to the medicine itself. A reanalysis published in 2025, which looked only at the studies that asked people systematically rather than waiting for them to volunteer symptoms, arrived at around half.

Almost all of that research involves people who had taken antidepressants for a few months. Very little of it describes what happens after several years, which is the situation many people reading this are actually in.

Symptoms after stopping escitalopram are common enough to plan for, but not so certain that you should expect them.

Withdrawal or relapse — how to tell them apart

Withdrawal symptoms tend to begin within days of a change, are often dominated by physical sensations such as dizziness and brain zaps, and settle relatively quickly if the previous dose is restored. A return of depression or anxiety tends to build over weeks, resembles how your original illness felt rather than a physical upset, and does not lift within a day or two if the dose goes back up.

That distinction is useful, but it is not perfect and it should not be used as a test you apply alone. NICE's guidance on withdrawal makes the point directly that withdrawal symptoms can be delayed, can be prolonged, and can affect mental health as well as physical health. Low mood and anxiety can be part of withdrawal, which is exactly what makes the two hard to separate.

If you cannot tell which you are dealing with, that is a normal position to be in and a good reason to speak to your prescriber rather than work it out on your own.

Why the last part is often the hardest

This catches people out, and it is worth understanding, because it is the most common reason a reduction that had been going well stops going well.

The relationship between the dose and the effect at the nerve cell is not a straight line. At higher doses the effect is close to its ceiling, so removing some milligrams changes relatively little. At low doses, removing the same number of milligrams makes a much bigger difference.

In practical terms, a reduction that you barely noticed near the top can feel like a much larger change near the bottom, even though the arithmetic looks identical. This is why NICE recommends reductions that are proportionate to the dose you are currently taking, so that the steps become smaller as the dose comes down, and it is why the final stretch often takes longer than everything before it.

It is a feature of how the medicine works. It is not a sign that something has gone wrong, and it is not a sign that you are doing it badly.

Lexapro taper schedules by starting dose (20, 10, 5 mg)

Escitalopram is potent per milligram, so a dose that sounds small is still doing a substantial amount of work. How to taper off Lexapro is less about a fixed milligram ladder and more about steps that get smaller as occupancy falls away from its ceiling.

From the top of the licensed range, early reductions often feel straightforward. The harder stretch is usually the lower end — including from 5 mg — because occupancy is still high there. Treating a low dose as “basically nothing” is the most common misunderstanding about this medicine.

The table above is an example planning schedule to review with your prescriber, not a sequence to follow on your own.

Preview a planning schedule →

If it gets worse: pausing and reinstatement

If a reduction is harder than you expected, speak to your prescriber. They can help you tell withdrawal from the original problem returning, and decide whether the plan needs more time or a liquid form for smaller steps.

This is educational information. Do not change your dose without your prescriber's input.

The forms escitalopram comes in

Escitalopram is made as tablets and as a liquid. Tablets are commonly 5 mg, 10 mg, 15 mg and 20 mg. There are also orodispersible tablets in the same strengths.

The UK liquid is an oral drops solution containing 20 mg in each millilitre, which works out at 1 mg per drop. The product information confirms the drops are equivalent to the tablets, so a milligram of drops does the same job as a milligram of tablet. In the US the equivalent product is an oral solution containing 1 mg per millilitre, given with an oral syringe.

If a plan you and your prescriber agree involves doses below what a tablet allows, liquid is usually how that is done. Whether that applies to you, and which product, is a question for them.

A note on what your leaflet says

The patient information leaflet in the box often says that when stopping, the dose should be reduced over a period of at least one to two weeks. NICE's guidance on withdrawal describes a slower, stepwise reduction that gets gentler as the dose falls, and says the process can take several months or more.

If your leaflet and your prescriber appear to disagree, this is usually why. Neither is making a mistake. The leaflet states a minimum; the guideline describes what many people actually need.

When to get help quickly

Contact your prescriber promptly if:

your mood drops significantly, or you feel worse than you did before you started
you have thoughts of harming yourself or ending your life. If you are in immediate danger, call emergency services — 911 in the US, or your local emergency number
symptoms after a dose change are getting worse rather than settling, or you cannot manage them
you become confused or unsteady, or feel physically unwell in a way that is new
you develop agitation with shivering, twitching, a racing heart or a fever
you become pregnant, or are planning to

Stopping escitalopram suddenly is not the answer to any of the above. Speak to someone first. Crisis lines for your region are listed at the bottom of this page.

The bottom line

The art of coming off Lexapro is respecting its potency: the top of the range can feel straightforward, then the last stretch needs more time than the milligrams suggest. Take the planning table to your prescriber, and ask about a liquid if the tablets cannot make the next step.

Key facts about hyperbolic antidepressant tapering

The calculator algorithm is based on peer-reviewed research and has been reviewed by our medical advisors to ensure the accuracy of the tapering model.

72%
discontinued their antidepressant using hyperbolic tapering strips in a real-world study
71% of the same people had previously tried to stop at least once and been unsuccessful; the study did not record which method those earlier attempts used. Figures come from tapering-strip research and may not generalise to every taper.
Source: Groot et al., Therapeutic Advances in Psychopharmacology 2021
56 days
median taper length in that tapering-strip study — not a target; many people taper over 6–12 months or longer
This median reflects tapering-strip use in one study. Your timeline depends on how long you have taken the medication, your withdrawal symptoms, and previous attempts — slower is often safer.
Source: Groot et al., Therapeutic Advances in Psychopharmacology 2021
10%
serotonin transporter occupancy per tapering step
This linear reduction prevents withdrawal. Slower, more gradual tapering over several months has shown greater success in reducing withdrawal symptoms than short tapers.
Source: Horowitz et al., The Lancet Psychiatry 2019

Claro — tapering companion

A protocol isn’t enough — you need support.

Tapering can take months, sometimes years. Claro helps you track each step, log symptoms, and spot when a reduction was too fast — with psychiatrist-reviewed guidance. Join early access while we launch the app.

Why an AI companion for tapering? →

Other medications with similar pharmacology or a higher population withdrawal-risk profile. Each guide links to a pre-filled hyperbolic schedule for that drug.

Other SSRI guides

Higher withdrawal risk

Pre-taper risk quiz Symptom checker Ask a psychiatrist Find help

Frequently asked questions about escitalopram

Common questions about how to taper off escitalopram, hyperbolic schedules, and withdrawal — written for people who want to come off antidepressants safely with their prescriber.

Can I stop escitalopram suddenly?

It is advised against, other than in unusual circumstances such as a severe reaction. Stopping abruptly makes withdrawal symptoms more likely and more intense. If you have already stopped and feel unwell, contact your prescriber rather than waiting it out.

Is a low dose of escitalopram basically nothing?

This is the most common misunderstanding about this medicine. Escitalopram is potent per milligram, so a dose that sounds small is still having a substantial effect. That is why stopping from a low dose is worth doing carefully rather than treating it as a formality.

How long does coming off take?

There is no fixed answer. It depends on how long you have taken it, what happened on previous attempts, and how you get on. NICE says withdrawal can be difficult and may take several months or more. Plans that follow the person rather than a timetable tend to go better.

Is escitalopram addictive?

Not in the usual sense. It does not cause craving, and people do not find themselves needing larger and larger doses. But the body does adapt to it, which is why stopping can cause symptoms. Those are two different things, and having withdrawal symptoms does not mean you were addicted.

Why is my maximum dose lower than someone else's?

The licensed maximum is 20 mg a day for adults, and usually 10 mg for people over 65 or with liver problems. This is because escitalopram can affect the heart's electrical rhythm at higher doses. If your prescriber has set a lower ceiling, there will be a reason, and it is a fair thing to ask about.

Does everyone get withdrawal symptoms?

No. The estimates vary widely. Some people stop with no difficulty at all. Symptoms after stopping escitalopram are common enough to plan for, not so certain that you should expect them.

Can I drink alcohol?

Alcohol is not recommended alongside escitalopram. How much that matters in your case is worth asking your prescriber about rather than guessing.

I feel fine. Doesn't that mean I can stop?

Feeling well is a necessary condition, not a sufficient one. Antidepressants are usually continued for a period after recovery precisely because the risk of becoming unwell again is highest in the months after symptoms settle. Feeling well is the right time to have the conversation, not the right time to act unilaterally.

What is an antidepressant tapering calculator?

An antidepressant tapering calculator is a free online medication taper calculator that turns a current dose into an example step-by-step reduction you can review with a prescriber. The Claro calculator uses the hyperbolic method: each step removes a similar percentage of receptor occupancy rather than the same number of milligrams. Take that draft to your clinician when you decide to wean off antidepressants — it is a planning tool, not a dose instruction.

Why use a tapering calculator?

A medication taper calculator turns receptor-occupancy research into a concrete hyperbolic taper schedule you can read in minutes. It is especially useful when you want to come off antidepressants gradually, because the last few milligrams cause the largest change in modelled occupancy. Use it to preview example steps and talk through liquid or split-tablet options when you wean off antidepressants with your prescriber.

How does an antidepressant taper calculator work?

The calculator models how much of your serotonin (or noradrenaline) transporter is occupied at each dose using a Hill-equation curve fitted to published PET studies. It then chooses dose reductions so that each step removes a roughly equal amount of occupancy — the hyperbolic method described by Horowitz and Taylor (2019). The schedule is then rounded to doses you can actually achieve with available tablets, capsules, or liquids in your region.

What is hyperbolic tapering and why is it recommended?

Hyperbolic tapering means reducing your dose by smaller and smaller milligram amounts as you get lower, so the change in receptor occupancy at each step stays about the same. It is recommended because antidepressants follow a hyperbolic dose-response curve: at low doses, small milligram changes have outsized effects. Hyperbolic tapering is endorsed in the Maudsley Deprescribing Guidelines (2024), the UK NICE NG222 guideline, and the Dutch multidisciplinary deprescribing document.

What is the safest way to taper off antidepressants?

The safest way is gradual, supervised, and individualised. Work with a prescriber, hold each dose for at least 2-4 weeks before reducing again, and use liquid or compounded formulations once tablets cannot be split small enough. If symptoms become severe, return to the previous stable dose, allow time to settle, then resume with smaller steps. This calculator is educational; do not change medication without clinical supervision.

How slowly should antidepressants be reduced?

Most people benefit from reductions of around 5-10% of the previous dose every 2-4 weeks, and even more slowly toward the end of the taper. Higher-risk drugs — paroxetine, venlafaxine, and duloxetine — typically need slower steps and longer holds. There is no fixed timeline: many people take 6-12 months to fully get off antidepressants and some take longer, especially after years of treatment.

What are common antidepressant withdrawal symptoms?

The most commonly reported antidepressant withdrawal symptoms include dizziness, "brain zaps" (brief electric-shock sensations), nausea, fatigue, insomnia, vivid dreams, headaches, irritability, anxiety, and mood swings. A 2024 Lancet Psychiatry meta-analysis (Henssler et al.) estimated discontinuation symptoms in around 31% of people, with about 2.8% experiencing severe symptoms. Earlier work (Davies & Read, 2019) reported higher rates of 56% across surveyed populations.

What is the difference between antidepressant withdrawal and relapse?

Withdrawal usually starts within days of a dose reduction, includes physical symptoms like dizziness or brain zaps, and improves when you reinstate the previous dose. Relapse of the original condition typically appears weeks later, is dominated by your original symptoms, and is not relieved within hours by reinstating. The Cosci & Chouinard (2020) framework is the standard taxonomy clinicians use to tell the two apart.

Is it dangerous to stop antidepressants cold turkey?

Stopping antidepressants cold turkey is widely discouraged. Sudden discontinuation increases the risk of severe withdrawal symptoms, including dizziness, brain zaps, and emotional changes, and can trigger reinstatement. Short half-life drugs such as paroxetine and venlafaxine carry the highest risk. If you have already stopped abruptly and feel unwell, contact your prescriber; reinstating the previous dose and then tapering more gradually is the standard recommendation.

Why are the last antidepressant dose reductions often the hardest?

Because the dose-occupancy curve is hyperbolic. At low doses, a 1-2 mg change can produce as much receptor change as a 10-20 mg change at higher doses. This is why people often feel fine for most of the taper and then struggle at the end. A medication taper calculator addresses this by making the final steps in tenths of a milligram, which usually requires a liquid formulation or compounded preparation.

Which antidepressants are hardest to taper off?

Paroxetine (Paxil/Seroxat) and venlafaxine (Effexor) are most often reported as the hardest antidepressants to come off, followed by duloxetine (Cymbalta). They share short half-lives and steep dose-occupancy curves, so missed doses or sharp reductions can trigger withdrawal symptoms within days. Fluoxetine (Prozac), with its very long half-life, is generally the easiest and is sometimes used as a "bridge" when switching off shorter-acting drugs.

Need a different dose or speed?

Use the guided builder to enter your current dose, region, and taper preset — then email a draft you can review with your prescriber.

Request custom protocol →

Clinical references

[1]Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms. The Lancet Psychiatry 2019.doi:10.1016/S2215-0366(19)30032-XProposes hyperbolic dose reduction based on receptor-occupancy curves; the methodological basis of every modern taper calculator.
[2]Horowitz MA, Taylor D. The Maudsley Deprescribing Guidelines. Wiley 2024.doi:10.1002/9781394291052Per-drug operational manual for hyperbolic tapering across SSRIs, SNRIs, benzodiazepines, gabapentinoids, and antipsychotics.
[3]Davies J, Read J. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects. Addictive Behaviors 2019.doi:10.1016/j.addbeh.2018.08.027Systematic review: 56% of people who discontinue antidepressants experience withdrawal effects; 46% rate them as severe.
[4]Henssler J et al. Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis. The Lancet Psychiatry 2024.doi:10.1016/S2215-0366(24)00133-0Meta-analysis of 79 studies (≈21,000 patients): pooled incidence of discontinuation symptoms ~31%; severe symptoms ~2.8%.
[5]Groot PC, van Os J. Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study. Therapeutic Advances in Psychopharmacology 2021.doi:10.1177/2045125321103932772% of patients successfully discontinued antidepressants after switching to the hyperbolic model; 71% had previously failed to come off without tapering strips.
[6]Groot PC, van Os J. Antidepressant tapering strips to help people come off medication: real-world outcomes. Therapeutic Advances in Psychopharmacology 2023.doi:10.1177/20451253231171518Of 1,194 patients using hyperbolic taper strips after previous failed attempts, ~71% successfully discontinued their antidepressant.
[7]Framer A. What I have learnt from helping thousands of people taper off antidepressants and other psychotropic medications. Therapeutic Advances in Psychopharmacology 2021.doi:10.1177/2045125321991274Describes the "windows and waves" pattern of withdrawal recovery and supports patient-led pacing.
[8]Hengartner MP et al. Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives. Therapeutic Advances in Psychopharmacology 2020.doi:10.1177/2045125320967183Descriptive analysis of 69 protracted withdrawal cases: median duration 79 weeks; 47% report suicidality during withdrawal.
[9]Cosci F, Chouinard G. Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. Psychotherapy and Psychosomatics 2020.doi:10.1159/000506868Taxonomy distinguishing new withdrawal symptoms, rebound, and persistent post-withdrawal disorder; the standard framework for withdrawal vs. relapse.
[10]Kalfas M et al. Incidence and Nature of Antidepressant Discontinuation Symptoms. JAMA Psychiatry 2025.doi:10.1001/jamapsychiatry.2025.1362Recent meta-analysis: dizziness was the most common discontinuation symptom in the first 2 weeks after stopping antidepressants, followed by nausea, vertigo, and nervousness.
[11]Gabriel M, Sharma V. Antidepressant discontinuation syndrome. Canadian Medical Association Journal 2017.doi:10.1503/cmaj.160991Clinical review of antidepressant discontinuation syndrome: onset within days of dose reduction, typical symptom course, and management.
[12]Papp A, Onton J. Brain Zaps: An Underappreciated Symptom of Antidepressant Discontinuation. The Primary Care Companion for CNS Disorders 2018.doi:10.4088/pcc.18m02311Characterises "brain zaps" — brief electric-shock sensations — as a common antidepressant discontinuation symptom.
[13]Wang J, Cosci F. Acute and persistent withdrawal syndromes following discontinuation of antidepressants in children and adolescents: a systematic review. Therapeutic Advances in Psychopharmacology 2025.doi:10.1177/20451253251404780Systematic review of acute and persistent antidepressant withdrawal syndromes; reinforces reducing only when stable and under supervision.
[14]Horowitz M, Taylor D. Distinguishing relapse from antidepressant withdrawal: clinical practice and antidepressant discontinuation studies. BJPsych Advances 2022.doi:10.1192/bja.2021.62Frames how clinicians can distinguish antidepressant withdrawal from relapse of the underlying condition.
[15]Sørensen A, Ruhé HG, Munkholm K. The relationship between dose and serotonin transporter occupancy of antidepressants — a systematic review. Molecular Psychiatry 2021.doi:10.1038/s41380-021-01285-wSystematic review of dose–SERT-occupancy relationships across antidepressants; confirms the hyperbolic curve underlying proportional tapering.
[16]Reeve R, Turner JR. Pharmacodynamic models: parameterizing the Hill equation, Michaelis-Menten, the logistic curve, and relationships among these models. Journal of Biopharmaceutical Statistics 2013.doi:10.1080/10543406.2012.756496Explains how the Hill equation, Michaelis-Menten, and logistic models relate — the mathematical basis for the occupancy curve used here.
[17]Preskorn SH. The use of biomarkers in psychiatric research: how serotonin transporter occupancy explains the dose-response curves of SSRIs. Journal of Psychiatric Practice 2012.LinkShows how SERT occupancy explains the non-linear dose–response curves of SSRIs.
[18]Cohrs D, Shapiro B. The relationship between SERT occupancy and extracellular serotonin concentration is hyperbolic, not linear: implications for safely tapering SRI antidepressants. SSRN (preprint) 2026.doi:10.2139/ssrn.6176553Argues the SERT-occupancy to serotonin relationship is itself hyperbolic, reinforcing proportional (hyperbolic) tapering.
[19]Moncrieff J et al. Evidence on antidepressant withdrawal: an appraisal and reanalysis of a recent systematic review. Psychological Medicine 2025.doi:10.1017/S0033291725100652Reappraisal of recent withdrawal-incidence evidence; relevant to how withdrawal rates are interpreted.
[20]Wilson E, Lader M. A review of the management of antidepressant discontinuation symptoms. Therapeutic Advances in Psychopharmacology 2015.doi:10.1177/2045125315612334Practical review of how to manage antidepressant discontinuation symptoms, including tapering and reinstatement.
[21]Groot PC, van Os J. Outcome of antidepressant drug discontinuation with tapering strips after 1–5 years. Therapeutic Advances in Psychopharmacology 2020.doi:10.1177/2045125320954609Long-term follow-up (1–5 years) of patients who discontinued antidepressants using hyperbolic taper strips.
[22]Gury C, Cousin F. Pharmacokinetics of SSRI antidepressants: half-life and clinical applicability. L'Encéphale 1999.LinkHalf-life data for SSRIs — explains why short-half-life drugs (paroxetine, venlafaxine) provoke faster withdrawal.
[23]Mayo Clinic. Antidepressant withdrawal: Is there such a thing?. Mayo Clinic — Expert Answers 2024.LinkPatient-facing explainer on antidepressant discontinuation symptoms and gradual tapering.
[24]NHS Scotland — Right Decision Service. Antidepressants — quality prescribing: difficulty withdrawing from an SSRI/SNRI. NHS Scotland 2024.LinkNHS Scotland guidance on recognising and managing difficulty withdrawing from SSRIs/SNRIs.
[25]The Carlat Psychiatry Report. Clinical pearls for hyperbolic tapering of psychiatric medications in older adults. The Carlat Report 2024.LinkPractical clinical pearls for applying hyperbolic tapering, including in older adults.
[26]Royal College of Psychiatrists. Stopping antidepressants — information for patients and carers. Royal College of Psychiatrists 2024.LinkRCPsych patient-facing guidance on coming off antidepressants safely.
[27]Meyer JH et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses. American Journal of Psychiatry 2004.doi:10.1176/appi.ajp.161.5.826PET-imaged SERT occupancy data for citalopram, sertraline, paroxetine, fluoxetine, and venlafaxine — the empirical basis for the hyperbolic curves in this calculator.
[28]Suhara T et al. High levels of serotonin transporter occupancy with low-dose clomipramine and escitalopram. Archives of General Psychiatry 2003.doi:10.1001/archpsyc.60.4.386Demonstrates high SERT occupancy at very low SSRI doses — supports the steep, hyperbolic dose-occupancy curve.
[29]National Institute for Health and Care Excellence (NICE). Depression in adults: treatment and management. NICE guideline [NG222]. NICE 2022.LinkUK national guideline endorsing proportional (hyperbolic) tapering and the use of liquid formulations to enable small final doses.
[30]National Institute for Health and Care Excellence (NICE). Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults. NICE guideline [NG215]. NICE 2022.LinkUK national guideline on withdrawal: symptoms can be delayed or prolonged, and reductions should get gentler as the dose falls.
[31]Lewis G et al. Maintenance or Discontinuation of Antidepressants in Primary Care. New England Journal of Medicine 2021.doi:10.1056/NEJMoa2106356Among people well enough that stopping seemed reasonable, 56% who stopped became unwell again within a year versus 39% who continued.
[32]Royal College of Psychiatrists. Stopping antidepressants — position statement (CR225). Royal College of Psychiatrists 2020.LinkRCPsych acknowledges withdrawal can be severe and long-lasting; recommends slow, individualised tapers.
[33]NHG et al. Multidisciplinary document: Discontinuation of SSRIs and SNRIs (2018; revised 2023). Multidisciplinary Document (Netherlands) 2018.LinkFirst national guideline to explicitly endorse hyperbolic tapering and the use of taper strips (compounded by Regenboog Apotheek).
[34]Medicines and Healthcare products Regulatory Agency (MHRA). Summary of Product Characteristics — SSRI and SNRI products (UK). electronic Medicines Compendium (emc) 2023.LinkAuthoritative UK formulary data (tablet strengths, oral solutions) used to validate the UK region in the calculator.
[35]U.S. Food and Drug Administration. Prescribing information (Structured Product Labeling) for SSRI/SNRI products. FDA / DailyMed 2024.LinkAuthoritative US formulary data (tablet strengths, oral solutions/concentrates) used to validate the US region in the calculator.
[36]Health Canada. Health Canada — Drug Product Database. Health Canada 2024.LinkAuthoritative Canadian formulary data used to validate the Canada region in the calculator.
[37]Therapeutic Goods Administration (TGA). Therapeutic Goods Administration — Australian Register of Therapeutic Goods (ARTG). TGA / ARTG 2024.LinkAuthoritative Australian formulary data used to validate the Australia region in the calculator.
[38]College ter Beoordeling van Geneesmiddelen (CBG-MEB). CBG-MEB — Medicines Information Bank (Netherlands). CBG-MEB 2024.LinkAuthoritative Dutch formulary data; cross-checked with Regenboog Apotheek taper-strip availability.
[39]Regenboog Apotheek, Cinetto. Taperingstrip.com — Regenboog Apotheek. Patient resource (NL) 2024.LinkPioneer of standardised taper strips referenced in the Dutch national guideline.

If you are in crisis or having thoughts of suicide, do not wait for an email response. Find a crisis helpline near you immediately →